Chronic Idiopathic Constipation (CIC) Treatment Market from 2021-2026 | Size, Share, Trends, Analysis, Growth, Top Key players and Forecast to 2026
SEATTLE, April 01, 2021, (PHARMIWEB) — Global Chronic Idiopathic Constipation (CIC) Treatment Market
Constipation is condition wherein the stool frequency reduces up to three times per week, with difficulty in stool passing. Chronic constipation is a highly common functional gastrointestinal disorder that adversely affects a patient’s life. Chronic idiopathic constipation (CIC) is a condition characterized with chronic symptoms of constipation, with no well-defined underlying causes. The symptoms of chronic idiopathic constipation includes infrequent bowel movements, hard stools, straining during defecation, feeling of incomplete evacuation, abdominal discomfort, and bloating sensation. Chronic idiopathic constipation is diagnosed by laboratory tests, endoscopy, radiological tests, magnetic resonance imaging, and physiological testing. Currently, very few approved treatment options are available for chronic idiopathic constipation, which is expected to be a major factor restrain growth of the chronic idiopathic constipation treatment market. However, this provides the leading global market players with ample opportunities to come up with novel treatments and thus strengthen their foothold in the global chronic idiopathic constipation treatment market.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1791
Global Chronic Idiopathic Constipation (CIC) Treatment Market Dynamics
Increasing number of clinical trials and approval of drug candidates introduced by pharmaceutical companies to fulfil the unmet medical needs of the CIC treatment are significant factors driving the global market growth. For instance, March 2018, Shire Plc received a new drug application from the U.S. FDA for its drug candidate, SHP555 (prucalopride) for the indication of chronic idiopathic constipation in adults. Moreover, in 2015, SHP555 (prucalopride) received approval from the European Commission for the symptomatic treatment of chronic constipation in adults, with failure of laxative treatment. Furthermore, Renexxion is conducting the Phase 2 clinical trial for Naronapride (ATI-7505) for the treatment of multiple gastrointestinal disorders, which include CIC. However, around 50% of patients with chronic constipation are said to be dissatisfied with their current treatment, primarily due to lack of efficacy, which highlights a continued medical need for more effective and safer therapeutic agents.
The use of alternate therapy such as home-based remedies and herbal medications, such as herbal laxatives, probiotic foods, etc., are however, predicted to restrain the global market growth.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3fwS5Zj
Global Chronic Idiopathic Constipation (CIC) Treatment Market – Regional Analysis
North America chronic idiopathic constipation treatment market holds dominant position owing to high percentage of population suffering from chronic constipation. For instance, according to European Journal of Pharmacology, 2017, in the U.S. 12%–19% of population suffers from chronic constipation. This is expected to aid in growth of the market in the region over the forecast period. However, Asia Pacific is expected to witness the fastest growth, owing to increasing prevalence of constipation in the Asian countries. According to Journal of Neurogastroenterology and Motility article 2016, in Asian countries such as China, Korea, Hong Kong, and India, the prevalence of constipation reportedly ranges from 8.2% to 16.8%. This is expected to support growth of the chronic idiopathic constipation treatment market size over the forecast period.
Global Chronic Idiopathic Constipation (CIC) Treatment Market – Competitive Analysis
The key players participating in the global chronic idiopathic constipation treatment market are Ironwood Pharmaceuticals, Allergan, Synergy Pharmaceuticals, Inc., Shire Plc, and Mallinckrodt plc.
The presence of very few market players provides a gigantic opportunity for new entrants in the global chronic idiopathic constipation treatment market. In February 2018, Mallinckrodt Plc, global specialty pharmaceutical company, announced acquisition of Sucampo Pharmaceuticals, Inc., a biopharmaceutical company. The acquisition assets includes its FDA approved blockbuster drug Amitiza (lubiprostone) for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C). The Sucampo Pharmaceuticals, Inc. also partnered with Par Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories Ltd. As a part of the agreement both the partners were granted a non-exclusive license to market Par’s generic version of lubiprostone in the U.S. from January, 2021. Such inorganic strategies of market players are expected to boost growth of the global market in the foreseeable future.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/chronic-idiopathic-constipation-cic-treatment-market-1791
On the basis of drug type:
By distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Table of Content
Global Chronic Idiopathic Constipation (CIC) Treatment Market Research Report
Section 1: Global Chronic Idiopathic Constipation (CIC) Treatment Industry Overview
Section 2: Global Economic Impact on Chronic Idiopathic Constipation (CIC) Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Chronic Idiopathic Constipation (CIC) Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Chronic Idiopathic Constipation (CIC) Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire